세계의 오토인젝터 시장 : 사용법별, 기술별, 투여 경로별, 치료 분야별, 용량별, 최종사용자별, 지역별 - 예측(-2030년)

The global autoinjectors market is projected to to expand to a value of USD 3.02 billion in 2030 from USD 1.40 billion in 2024, with a significant CAGR of 13.6%. The autoinjector finished formulations market is projected to surge to a value of USD 134.27 billion in 2030 from USD 67.30 billion in 2024, growing at a CAGR of 12.2%.

Favorable reimbursement policies in North America and Europe coupled with launch of biosimilars across the globe are some of the factors contributing towards the market growth.

"The manual autoinjectors segment accounted for the largest share in 2023."

On the basis of technology, the autoinjectors market is further segmented into manual, and automatic. The manual autoinjectors segment dominated the market in 2023, owing to the rise in demand due to rising incidence of conditions such as diabetes, multiple sclerosis, and rheumatoid arthritis. Furthermore, cost-effectiveness and expanding new therapeutic applications, is likely to increase their overall market potential for manual autoinjectors in coming years.

"By end user, the home care settings segment accounted for the largest share in the autoinjectors market."

The end user segment in the autoinjectors market is segmented into home care settings, hospitals & clinics, and ambulatory care settings. In 2023, the home care settings segment accounted for the largest share owing to increased adoption of autoinjectors at home care settings. Furthermore, cost effectiveness, launch of user friendly autoinjector devices is likely to boost the growth of the home care settings segment. Use of autoinjectors for emergency situations such as anaphylactic reactions is likely to increase demand for autoinjectors in hospitals & clinics further propelling the growth of the market.

"North America: the largest share of the autoinjectors market"

North America dominated the autoinjectors market in 2023 and likely continue dominance during the forecast period. Well-developed healthcare infrastructure, prevalence of chronic diseases such as diabetes, rheumatoid arthritis, and multiple sclerosis and favourable reimbursement policies in North America are some of the factors influencing the use of autoinjectors subsequently contributing towards market growth. The Asia Pacific autoinjectors market is predicted to grow at the significant CAGR during the forecast period of 2024-2030. The growth of the region is primarily attributed to the presence of large number of pharmaceutical and biopharmaceutical companies and growing number of regulatory apporvals for autoinjectors in the region especially China, India and South Korea.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10% and Middle East & Africa- 5%

List of Companies Profiled in the Report:

• SHL Medical AG (Switzerland)
• Ypsomed AG (Switzerland)
• Becton, Dickinson and Company (BD) (US)
• Recipharm AB (Sweden)
• West Pharmaceutical Services, Inc.(US)
• Phillips-Medisize (US)
• Halozyme, Inc. (US)
• Owen Mumford Ltd. (UK)
• Abbvie Inc. (US)
• Eli Lilly and Company (US)
• Amgen Inc. (US)
• Novo Nordisk A/S (Denmark)
• Jonhson & Jonhson Services Inc. (US)
• Sanofi (France)
• GSK plc (UK)
• Gerresheimer AG (Germany)
• Haselmeier (Germany)
• Oval Medical Technologies Ltd. (UK)
• Kaleo, Inc. (US)
• Solteam Incorporation Co., Ltd. (China)
• Elcam Drug Delivery Devices (Israel)
• Crossject (France)
• Jabil, Inc. (US)
• Congruence Medical Solutions LLC (US)
• Midas Pharma GMBH (Germany)

Research Coverage:

This research report categorizes the autoinjectors market usage (reusable and disposable), technology (manual and automatic), route of administration (intramuscular and subcutaneous), therapy area (rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, obesity and other therapy areas), Volume (upto 3ml and above 3 ml) and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). and by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the autoinjectors market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the autoinjectors market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the autoinjector devices and finished formulations market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (rising prevalence of chronic diseases, increasing regulatory approvals for autoinjectors, high demand for biologics & biosimilars, growing adoption of self-administered medicines, government support and favorable reimbursement policies), restraints (Focus on needle-free drug delivery systems and prevalence of needle phobia ), opportunities (Impending patent expiry of biological molecules, launch of technologically-advanced autoinjectors) and Challenges (Development of autoinjectors for multiple drug viscosities) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the autoinjectors market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the autoinjectors market
• Competitive Assessment: SHL Medical AG (Switzerland), Ypsomed AG (Switzerland), Becton, Dickinson and Company (BD) (US), Abbvie Inc. (US), Eli Lilly and Company (US), Amgen Inc. (US), and Novo Nordisk A/S (Denmark) among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 INCLUSIONS & EXCLUSIONS
• 1.4 STUDY SCOPE
  • 1.4.1 SEGMENTS CONSIDERED
  • 1.4.2 YEARS CONSIDERED
  • 1.4.3 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET SIZE ESTIMATION METHODOLOGY OF AUTOINJECTORS DEVICES
• 2.3 MARKET SIZE ESTIMATION OF AUTOINJECTOR FINISHED FORMULATIONS
  • 2.3.1 INSIGHTS FROM PRIMARY EXPERTS
  • 2.3.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
• 2.4 MARKET GROWTH RATE PROJECTIONS
• 2.5 DATA TRIANGULATION
• 2.6 RESEARCH ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS
• 2.8 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 AUTOINJECTORS MARKET OVERVIEW
• 4.2 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE AND COUNTRY (2023)
• 4.3 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION AND COUNTRY (2023)
• 4.4 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2024 VS. 2030 (USD MILLION)
• 4.5 AUTOINJECTORS MARKET SHARE, BY TECHNOLOGY, 2023
• 4.6 AUTOINJECTOR DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.7 AUTOINJECTOR FINISHED FORMULATIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising prevalence of chronic diseases
    • 5.2.1.2 Increasing regulatory approvals for autoinjectors
    • 5.2.1.3 High demand for biosimilars and biologics
    • 5.2.1.4 Growing adoption of self-administered medicines
    • 5.2.1.5 Government support and favorable reimbursement policies
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Focus on needle-free drug delivery systems and prevalence of needle phobia
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Impending patent expiry of biological molecules
    • 5.2.3.2 Launch of technologically advanced autoinjectors
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Development of autoinjectors for multiple drug viscosities
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 VALUE CHAIN ANALYSIS
  • 5.4.1 VALUE CHAIN ANALYSIS: AUTOINJECTOR DEVICE MANUFACTURERS (PLATFORM PROVIDERS)
  • 5.4.2 VALUE CHAIN ANALYSIS: AUTOINJECTOR FINISHED FORMULATION MANUFACTURERS
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 ECOSYSTEM ANALYSIS
  • 5.6.1 AUTOINJECTOR PROVIDERS
  • 5.6.2 END USERS
  • 5.6.3 REGULATORY BODIES
• 5.7 REGULATORY LANDSCAPE
  • 5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.7.1.1 North America
    • 5.7.1.2 Europe
    • 5.7.1.3 Asia Pacific
    • 5.7.1.4 Rest of the World
  • 5.7.2 REGULATORY FRAMEWORK
    • 5.7.2.1 North America
    • 5.7.2.2 Europe
    • 5.7.2.3 Asia Pacific
    • 5.7.2.4 Rest of the World
• 5.8 PORTER'S FIVE FORCES ANALYSIS
  • 5.8.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.8.2 BARGAINING POWER OF SUPPLIERS
  • 5.8.3 BARGAINING POWER OF BUYERS
  • 5.8.4 THREAT OF SUBSTITUTES
  • 5.8.5 THREAT OF NEW ENTRANTS
• 5.9 TRADE DATA ANALYSIS
  • 5.9.1 IMPORT DATA FOR PRODUCTS (INCLUDING AUTOINJECTORS)
  • 5.9.2 EXPORT DATA FOR PRODUCTS (INCLUDING AUTOINJECTORS)
• 5.10 TECHNOLOGY ANALYSIS
  • 5.10.1 KEY TECHNOLOGIES
    • 5.10.1.1 Injection mechanism technology
    • 5.10.1.2 Electronic and connectivity solutions
  • 5.10.2 ADJACENT TECHNOLOGIES
    • 5.10.2.1 Wearable drug delivery devices
    • 5.10.2.2 Implantable drug delivery systems
  • 5.10.3 COMPLEMENTARY TECHNOLOGIES
    • 5.10.3.1 Power assistance mechanisms
    • 5.10.3.2 Advanced needle technology
• 5.11 PATENT ANALYSIS
  • 5.11.1 METHODOLOGY
  • 5.11.2 PATENTS APPLIED AND GRANTED, 2014-2025
• 5.12 INDICATIVE PRICING ANALYSIS
  • 5.12.1 AVERAGE SELLING PRICE TREND, BY PRODUCT TYPE
  • 5.12.2 AVERAGE SELLING PRICE, BY USAGE
  • 5.12.3 INDICATIVE PRICING ANALYSIS FOR AUTOINJECTOR FINISHED FORMULATIONS, BY KEY PLAYER
  • 5.12.4 INDICATIVE PRICING ANALYSIS FOR AUTOINJECTOR FINISHED FORMULATIONS, BY REGION
• 5.13 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.14 INVESTMENT AND FUNDING SCENARIO
• 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.15.1.1 Key stakeholders in buying process for autoinjector devices
    • 5.15.1.2 Key stakeholders in buying process for autoinjector finished formulations
  • 5.15.2 KEY BUYING CRITERIA
    • 5.15.2.1 Key buying criteria for autoinjector devices
    • 5.15.2.2 Key buying criteria for autoinjector finished formulations
• 5.16 IMPACT OF GENERATIVE AI ON AUTOINJECTORS MARKET

6 AUTOINJECTORS MARKET, BY USAGE

• 6.1 INTRODUCTION
• 6.2 DISPOSABLE AUTOINJECTORS
  • 6.2.1 EASE OF USE AND REDUCED RISK OF NEEDLESTICK INJURIES TO PROPEL MARKET GROWTH
• 6.3 REUSABLE AUTOINJECTORS
  • 6.3.1 COST-EFFECTIVENESS, VERSATILITY, AND SUSTAINABILITY TO FUEL MARKET GROWTH

7 AUTOINJECTORS MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 MANUAL AUTOINJECTORS
  • 7.2.1 USER-FRIENDLY DESIGN AND INCREASED PATIENT CONTROL TO AUGMENT MARKET GROWTH
• 7.3 AUTOMATIC AUTOINJECTORS
  • 7.3.1 EASE OF ACCURATE DOCUMENTATION AND COMPREHENSIVE PATIENT RECORDS TO SUPPORT MARKET GROWTH

8 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION

• 8.1 INTRODUCTION
• 8.2 SUBCUTANEOUS ROUTE OF ADMINISTRATION
  • 8.2.1 EASE OF USE, RAPID ABSORPTION, AND SUITABILITY FOR SELF-ADMINISTRATION TO AID MARKET GROWTH
• 8.3 INTRAMUSCULAR ROUTE OF ADMINISTRATION
  • 8.3.1 NEED FOR PRECISE DOSE DELIVERY IN EMERGENCY CLINICAL SETTINGS TO DRIVE MARKET

9 AUTOINJECTORS MARKET, BY THERAPY AREA

• 9.1 INTRODUCTION
• 9.2 RHEUMATOID ARTHRITIS
  • 9.2.1 HIGH DISEASE PREVALENCE AND NEED FOR FREQUENT DOSING TO DRIVE MARKET
• 9.3 DIABETES
  • 9.3.1 LARGE DIABETIC POPULATION AND EASE OF ADMINISTRATION TO STIMULATE DEMAND
• 9.4 MULTIPLE SCLEROSIS
  • 9.4.1 AVAILABILITY OF COST-EFFECTIVE GENERIC ORAL MULTIPLE SCLEROSIS DRUGS TO LIMIT MARKET GROWTH
• 9.5 ANAPHYLAXIS
  • 9.5.1 REQUIREMENT FOR PROMPT INITIAL TREATMENT FOR PATIENTS WITH FOOD ALLERGIES TO FUEL MARKET GROWTH
• 9.6 OBESITY
  • 9.6.1 INCREASING FOCUS ON WEIGHT MANAGEMENT TO BOOST MARKET GROWTH
• 9.7 OTHER THERAPY AREAS

10 AUTOINJECTORS MARKET, BY VOLUME

• 10.1 INTRODUCTION
• 10.2 UP TO 3ML VOLUME AUTOINJECTORS
  • 10.2.1 RISING PREVALENCE OF AUTOIMMUNE DISORDERS AND LONG-TERM CHRONIC DISEASES TO PROPEL MARKET GROWTH
• 10.3 ABOVE 3ML VOLUME AUTOINJECTORS
  • 10.3.1 INCREASING FOCUS ON COMPLEX TREATMENTS WITH HIGH-VISCOSITY DRUGS TO DRIVE MARKET

11 AUTOINJECTORS MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 HOME CARE SETTINGS
  • 11.2.1 COST-EFFECTIVENESS AND INCREASED AVAILABILITY OF HOME CARE SUPPORT SERVICES TO PROPEL MARKET GROWTH
• 11.3 HOSPITALS & CLINICS
  • 11.3.1 TECHNOLOGICAL ADVANCEMENTS AND AVAILABILITY OF REAL-TIME PATIENT DATA TO SUPPORT MARKET GROWTH
• 11.4 AMBULATORY CARE SETTINGS
  • 11.4.1 GROWING DEMAND FOR OUTPATIENT SERVICES TO FUEL MARKET GROWTH

12 AUTOINJECTORS MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 US
    • 12.2.1.1 US to dominate North American autoinjectors market during forecast period
  • 12.2.2 CANADA
    • 12.2.2.1 Rising geriatric population and increasing prevalence of food allergies to propel market growth
• 12.3 EUROPE
  • 12.3.1 GERMANY
    • 12.3.1.1 Favorable government initiatives and regulatory trends to aid market growth
  • 12.3.2 UK
    • 12.3.2.1 High prevalence of allergic conditions and increased incidence of lifestyle diseases to boost market growth
  • 12.3.3 FRANCE
    • 12.3.3.1 High prevalence of diabetes and favorable reimbursement policies to support market
  • 12.3.4 ITALY
    • 12.3.4.1 Rising healthcare expenditure and increasing geriatric population to augment market growth
  • 12.3.5 SPAIN
    • 12.3.5.1 Favorable reimbursement scenario and presence of universal health coverage facility to aid market growth
  • 12.3.6 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 JAPAN
    • 12.4.1.1 Large geriatric population and improved healthcare infrastructure to drive market
  • 12.4.2 CHINA
    • 12.4.2.1 Increasing prevalence of food allergies and anaphylaxis to fuel market growth
  • 12.4.3 INDIA
    • 12.4.3.1 Increasing burden of diabetes and cardiovascular diseases to spur market growth
  • 12.4.4 SOUTH KOREA
    • 12.4.4.1 Increased regulatory approvals and strong clinical pipeline by domestic players to propel market
  • 12.4.5 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 BRAZIL
    • 12.5.1.1 Rising adoption of autoinjectors and growing prevalence of chronic diseases to augment market growth
  • 12.5.2 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST & AFRICA
  • 12.6.1 GCC COUNTRIES
    • 12.6.1.1 High healthcare spending capacity and favorable regulatory scenario to drive market
  • 12.6.2 REST OF MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2021-2025
  • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AUTOINJECTORS MARKET
• 13.3 REVENUE ANALYSIS, 2021-2023
  • 13.3.1 REVENUE ANALYSIS: AUTOINJECTOR DEVICES MARKET
  • 13.3.2 REVENUE ANALYSIS: AUTOINJECTOR FINISHED FORMULATIONS MARKET
• 13.4 MARKET SHARE ANALYSIS, 2023
  • 13.4.1 MARKET SHARE ANALYSIS: AUTOINJECTOR DEVICES MARKET
  • 13.4.2 MARKET SHARE ANALYSIS: AUTOINJECTOR FINISHED FORMULATIONS MARKET
• 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 13.5.1 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 13.5.1.1 Stars
    • 13.5.1.2 Emerging leaders
    • 13.5.1.3 Pervasive players
    • 13.5.1.4 Participants
  • 13.5.2 AUTOINJECTOR FINISHED FORMULATIONS MARKET: COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 13.5.2.1 Stars
    • 13.5.2.2 Emerging leaders
    • 13.5.2.3 Pervasive players
    • 13.5.2.4 Participants
  • 13.5.3 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 13.5.3.1 Company footprint
    • 13.5.3.2 Region footprint
    • 13.5.3.3 Usage footprint
    • 13.5.3.4 Volume footprint
    • 13.5.3.5 Route of administration footprint
• 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 13.6.1 PROGRESSIVE COMPANIES
  • 13.6.2 RESPONSIVE COMPANIES
  • 13.6.3 DYNAMIC COMPANIES
  • 13.6.4 STARTING BLOCKS
  • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 13.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 13.7.1 FINANCIAL METRICS
  • 13.7.2 COMPANY VALUATION
• 13.8 BRAND/PRODUCT COMPARISON
• 13.9 COMPETITIVE SCENARIO
  • 13.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 13.9.2 DEALS
  • 13.9.3 EXPANSIONS
• 13.10 DEVICES FOR LARGE-VOLUME FORMULATIONS
• 13.11 DEVICES FOR HIGHLY VISCOUS FORMULATIONS
• 13.12 INSIGHTS ON FUTURE AREAS OF FOCUS IN AUTOINJECTORS MARKET

14 COMPANY PROFILES

• 14.1 KEY PLAYERS: AUTOINJECTOR DEVICES MARKET
  • 14.1.1 SHL MEDICAL AG
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Product launches
      • 14.1.1.3.2 Deals
      • 14.1.1.3.3 Expansions
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Key strengths
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses and competitive threats
  • 14.1.2 YPSOMED AG
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Product launches
      • 14.1.2.3.2 Deals
      • 14.1.2.3.3 Expansions
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Key strengths
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses and competitive threats
  • 14.1.3 BECTON, DICKINSON AND COMPANY (BD)
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Deals
      • 14.1.3.3.2 Other developments
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses and competitive threats
  • 14.1.4 RECIPHARM AB
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products offered
  • 14.1.5 WEST PHARMACEUTICAL SERVICES, INC.
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Expansions
  • 14.1.6 PHILLIPS-MEDISIZE
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Product launches
  • 14.1.7 HALOZYME, INC.
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products offered
  • 14.1.8 OWEN MUMFORD LTD.
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Product launches
      • 14.1.8.3.2 Deals
      • 14.1.8.3.3 Expansions
• 14.2 KEY PLAYERS: AUTOINJECTOR FINISHED FORMULATIONS MARKET
  • 14.2.1 ABBVIE INC.
    • 14.2.1.1 Business overview
    • 14.2.1.2 Products offered
    • 14.2.1.3 Recent developments
      • 14.2.1.3.1 Product launches and approvals
  • 14.2.2 ELI LILLY AND COMPANY
    • 14.2.2.1 Business overview
    • 14.2.2.2 Products offered
    • 14.2.2.3 Recent developments
      • 14.2.2.3.1 Product approvals
      • 14.2.2.3.2 Deals
  • 14.2.3 AMGEN INC.
    • 14.2.3.1 Business overview
    • 14.2.3.2 Products offered
    • 14.2.3.3 Recent developments
      • 14.2.3.3.1 Product launches
  • 14.2.4 NOVO NORDISK A/S
    • 14.2.4.1 Business overview
    • 14.2.4.2 Products offered
    • 14.2.4.3 Recent developments
      • 14.2.4.3.1 Product approvals
      • 14.2.4.3.2 Deals
      • 14.2.4.3.3 Expansions
      • 14.2.4.3.4 Other developments
  • 14.2.5 JOHNSON & JOHNSON SERVICES, INC.
    • 14.2.5.1 Business overview
    • 14.2.5.2 Products offered
  • 14.2.6 SANOFI
    • 14.2.6.1 Business overview
    • 14.2.6.2 Products offered
  • 14.2.7 GSK PLC
    • 14.2.7.1 Business overview
    • 14.2.7.2 Products offered
    • 14.2.7.3 Recent developments
      • 14.2.7.3.1 Product approvals
• 14.3 OTHER PLAYERS
  • 14.3.1 GERRESHEIMER AG
  • 14.3.2 HASELMEIER
  • 14.3.3 SMC LTD
  • 14.3.4 KALEO, INC.
  • 14.3.5 SOLTEAM INCORPORATION CO., LTD.
  • 14.3.6 ELCAM DRUG DELIVERY DEVICES
  • 14.3.7 CROSSJECT
  • 14.3.8 JABIL INC.
  • 14.3.9 CONGRUENCE MEDICAL SOLUTIONS LLC
  • 14.3.10 MIDAS PHARMA GMBH

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS